Crestone, Inc.
Boulder, CO
- UEI
- EDSLAP2J1BL8
- CAGE
- 5RDJ6
- Primary NAICS
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- SAM.gov registration
- Active through
Company facts
- FY2025 rankings
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- SAM.gov registration date
- Physical address
- 6075 Longbow Dr #130, Boulder, CO 80301, USA
- Website
- crestonepharma.com
- Founded
- 2009
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $2,716,661 |
| FY2025 | $5,484,913 |
| FY2024 | $5,665,240 |
| FY2023 | $6,279,048 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Department of Health and Human Services | $2,716,692 |
Contract awards
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Venatorx Pharmaceuticals Inc. | Chadds Ford, PA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Curza Inc. | Salt Lake City, UT | — |
| Microbiotix, Inc. | Worcester, MA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Basilea Pharmaceutica International Ltd, Allschwil | Allschwil, BL | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Biological Mimetics, Inc. | Frederick, MD | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
About the company
Crestone, Inc. is a for-profit biotechnology company based in Boulder, Colorado, specializing in developing novel therapeutic treatments for antibiotic-resistant bacterial infections. Registered in SAM.gov since October 2009, the company has established itself as a key research partner for federal agencies, particularly in the medical and infectious disease research domains. The company focuses on synthesizing and testing laboratory services, with a strong emphasis on developing innovative pharmaceutical compounds targeting challenging medical conditions.
Through federal contract awards, Crestone, Inc. has consistently worked with the Department of Veterans Affairs' Veterans Integrated Service Network 19 and the National Institute of Allergy and Infectious Diseases (NIAID), securing multiple contracts for advanced research initiatives. The company has been awarded several purchase orders and definitive contracts, including a significant $23,548,569 cost-plus-fixed-fee contract to advance a small-molecule compound (CRS0540) through investigational new drug filing and Phase I clinical studies. These contracts have ranged from $98,980 to over $23 million, primarily involving synthesis and testing of novel antibiotic chemical compounds. The contracts have been both small business set-aside and non-set-aside, demonstrating the company's versatility in federal contracting. The work has consistently centered on researching and developing treatments for antibiotic-resistant infections, with a particular focus on creating innovative therapeutic approaches.
In the realm of federal grant awards, Crestone, Inc. has received funding from the National Institute of Allergy and Infectious Diseases to support cutting-edge medical research. A notable grant (R43AI179346) focuses on developing a novel small molecule therapeutic for acute Graft-versus-Host Disease (GVHD), specifically targeting the prevention and treatment of complications associated with allogeneic hematopoietic cell transplantation. The grant research explores the potential of their compound CRS3123 to selectively suppress pathogenic enterococci in the gut microbiome, which could potentially reduce GVHD occurrence without disrupting beneficial gut bacteria. This grant award, valued at an undisclosed amount, demonstrates the company's commitment to innovative medical research that addresses complex medical challenges through targeted microbiological interventions.
Quick answers
Is Crestone, Inc. registered in SAM.gov?
Yes. Crestone, Inc.'s SAM.gov registration is active through May 1, 2027.
What is Crestone, Inc.'s CAGE code?
Crestone, Inc.'s CAGE code is 5RDJ6, and its Unique Entity ID (UEI) is EDSLAP2J1BL8.
How much has Crestone, Inc. received in federal contracts?
Federal contracts obligated $5,484,913 to Crestone, Inc. in fiscal year 2025 and $20,145,862 in fiscal years 2023 through 2027.
How does Crestone, Inc. rank among federal contractors?
Crestone, Inc. ranked #34 in PSC AN12 and #80 in NAICS 541714 in FY2025.
What is Crestone, Inc.'s most recent federal award?
Crestone, Inc.'s most recent federal contract award is Synthesis and testing laboratory services for research (36C25924P1167), from Veterans Integrated Service Network 19 (VHA), on September 1, 2024.
On GovTribe
See Crestone, Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors